Menzies study to trial moxidectin to treat scabies
The Menzies School of Health Research is involved in a ground-breaking study that has the potential to improve the treatment of scabies around the world. Scabies is estimated to affect more than 200 million people.
Collaborating with Medicines Development for Global Health, the research team at Menzies is trialling the use of the drug moxidectin as a single-dose oral medicine to treat the scabies infection.
Menzies honorary clinical fellow, dermatologist, Dr Dev Tilakaratne demonstrates the reflectance confocal microscope (RCM) machine which allows him to see what the scabies mite and egg look like on a participant’s hand.
Link to The Australian Article (behind paywall)